Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target

Stock Track10-29

NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused genetic testing company has captured investors' attention with its robust revenue growth despite widening losses.

According to the Q3 earnings report, NeoGenomics demonstrated strong revenue growth, signaling positive momentum in its core business. While the company's losses have increased, the market appears to be focusing on the top-line expansion, suggesting confidence in the company's long-term prospects.

Adding to the positive sentiment, TD Cowen has raised its price target for NeoGenomics from $12 to $14, indicating increased optimism about the company's future performance. However, it's worth noting that Benchmark Co. has maintained its Hold rating on the stock, suggesting a more cautious stance. The mixed analyst views highlight the complex landscape NeoGenomics is navigating as it pursues growth in the competitive genetic testing market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178868251?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178868251","market":"us","top_or_hot":-1,"title":"Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target","media":"Stock Track","content":"<p>NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused genetic testing company has captured investors' attention with its robust revenue growth despite widening losses.</p>\n\n<p>According to the Q3 earnings report, NeoGenomics demonstrated strong revenue growth, signaling positive momentum in its core business. While the company's losses have increased, the market appears to be focusing on the top-line expansion, suggesting confidence in the company's long-term prospects.</p>\n\n<p>Adding to the positive sentiment, TD Cowen has raised its price target for NeoGenomics from $12 to $14, indicating increased optimism about the company's future performance. However, it's worth noting that Benchmark Co. has maintained its Hold rating on the stock, suggesting a more cautious stance. The mixed analyst views highlight the complex landscape NeoGenomics is navigating as it pursues growth in the competitive genetic testing market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused genetic testing company has captured investors' attention with its robust revenue growth despite widening losses.</p>\n\n<p>According to the Q3 earnings report, NeoGenomics demonstrated strong revenue growth, signaling positive momentum in its core business. While the company's losses have increased, the market appears to be focusing on the top-line expansion, suggesting confidence in the company's long-term prospects.</p>\n\n<p>Adding to the positive sentiment, TD Cowen has raised its price target for NeoGenomics from $12 to $14, indicating increased optimism about the company's future performance. However, it's worth noting that Benchmark Co. has maintained its Hold rating on the stock, suggesting a more cautious stance. The mixed analyst views highlight the complex landscape NeoGenomics is navigating as it pursues growth in the competitive genetic testing market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEO","symbol_name":"NeoGenomics","start_time":0,"source_url":"","article_id":"1178868251","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178868251","pubTimestamp":1761746264,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEO":"NeoGenomics"},"translate_title":"个股赛道|NeoGenomics大涨5.24%，Q3营收增长强劲，目标价上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused genetic testing company has captured investors' attention with its robust revenue growth despite widening losses.\nAccording to the Q3 earnings report, NeoGenomics demonstrated strong revenue growth, signaling positive momentum in its core business. While the company's losses have increased, the market appears to be focusing on the top-line expansion, suggesting confidence in the company's long-term prospects.\nAdding to the positive sentiment, TD Cowen has raised its price target for NeoGenomics from $12 to $14, indicating increased optimism about the company's future performance. However, it's worth noting that Benchmark Co. has maintained its Hold rating on the stock, suggesting a more cautious stance. The mixed analyst views highlight the complex landscape NeoGenomics is navigating as it pursues growth in the competitive genetic testing market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178868251","isCrawlerRequest":true}